Clinical Trials Browser

Phase 1/2 × Interventional × eprenetapopt × Clear all

NCT04383938 2025-05-13

Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignancies

Phase 1/2 Completed

40 enrolled 11 charts

GastrointestinalGenitourinaryThoracic

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Stomach Neoplasms

NCT02098343 2025-03-17

p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin Combination Chemotherapy With or Without APR-246

Phase 1/2 Completed

247 enrolled 15 charts

Ovarian Neoplasms, Recurrence

NCT04419389 2025-03-17

R/R

Phase 1/2 Terminated

1 enrolled 4 charts

LymphoidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell

NCT03072043 2022-01-24

Phase 1b/2 Safety and Efficacy of APR-246 w/Azacitidine for tx of TP53 Mutant Myeloid Neoplasms

Phase 1/2 Completed

55 enrolled 15 charts

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT02999893 2021-12-13

APROC

Phase 1/2 Terminated

Gastrointestinal

Esophageal Neoplasms

NCT03588078 2020-01-30

Study of the Safety and Efficacy of APR-246 in Combination With Azacitidine

Phase 1/2 Unknown

MyeloidOther hematologic neoplasm

Myeloproliferative Disorders, Leukemia, Myelomonocytic, Chronic

NCT03391050 2019-07-31

A Study of APR-246 in Combination With Dabrafenib in Resistant Patients With BRAF V600 Mutant Melanoma

Phase 1/2 Terminated

Melanoma, Neoplasm Metastasis, Skin Neoplasms